The International Journal of Romanian Society of Endocrinology / Registered in 1938

in ISI Thomson Master Journal List

January - March 2018, Volume 14, Issue 1
General Endocrinology

Moise LG, Marta DS, Rascu A, Moldoveanu E

Serum Lipoprotein-Associated Phospholipase A2 in Males With Metabolic Syndrome and Obstructive Sleep Apnea

Acta Endo (Buc) 2018, 14 (1): 36-42
doi: 10.4183/aeb.2018.36

Context. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular diseases (CVD) risk estimation with high specificity for vascular inflammation. Few studies have investigated Lp-PLA2 levels in patients with metabolic syndrome (MetS) and obstructive sleep apnea syndrome (OSAS). Objective. This study aimed to evaluate the role of Lp-PLA2 levels as a marker of vascular inflammation that contributes to cardiometabolic dysfunction in patients with MetS and OSAS. Design. This is a prospective case-control study. Subjects and Methods. 83 men were enrolled. Following anthropometric measurements, laboratory analysis and overnight sleep study, patients were divided into three groups: MetS, OSAS with/without MetS. Serum Lp-PLA2 levels were determined by ELISA method. Results. Serum Lp-PLA2 levels were statistically significant among the three groups and were higher in OSAS with MetS group than those without MetS. A significant positive relationship between increased Lp-PLA2 level and CRP (C-reactive protein) and apnea–hypopnea index (AHI) was found. Average oxygen saturation (AvO2) and the lowest oxygen saturation were negatively correlated with Lp-PLA2. The number of desaturation events, oxygen desaturation index, AvO2, AHI and CRP were significant predictors of Lp-PLA2. Conclusions. Lp-PLA2 levels are associated with OSAS severity and might play an important role in predicting CVD in OSAS with/without MetS

Keywords: lipoprotein-associated phospholipase A2, metabolic syndrome, obstructive sleep apnea, cardiovascular disease risk.

Correspondence: Daciana-Silvia Marta, PhD, “Victor Babe?” National Institute of Pathology, Ultrastructural Pathology Department, 99-101 Splaiul Independen?ei, District 5, Code 050096, Bucharest, Romania. E-mail: